Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:INDP NASDAQ:LONA NASDAQ:TKNO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.78-3.8%$2.95$1.66▼$4.54$272.19M2.12.08 million shs1.04 million shsINDPIndaptus Therapeutics$2.64+4.8%$2.61$0.92▼$10.91$298.96M1.11490,650 shs19,496 shsLONAAthira Pharma$7.56-5.3%$8.89$3.24▼$14.21$71.02M2.0154,387 shs9,890 shsTKNOAlpha Teknova$5.24-1.9%$4.87$1.91▼$6.68$280.94M0.62191,069 shs100,146 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+0.35%-8.54%+7.43%-13.21%-8.25%INDPIndaptus Therapeutics+2.44%-4.18%-35.38%-26.74%-76.88%LONAAthira Pharma+5.42%-16.18%-2.44%-12.88%+797,999,900.00%TKNOAlpha Teknova+0.75%-1.29%+1.91%+65.84%+29.93%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$2.78-3.8%$2.95$1.66▼$4.54$272.19M2.12.08 million shs1.04 million shsINDPIndaptus Therapeutics$2.64+4.8%$2.61$0.92▼$10.91$298.96M1.11490,650 shs19,496 shsLONAAthira Pharma$7.56-5.3%$8.89$3.24▼$14.21$71.02M2.0154,387 shs9,890 shsTKNOAlpha Teknova$5.24-1.9%$4.87$1.91▼$6.68$280.94M0.62191,069 shs100,146 shs7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine+0.35%-8.54%+7.43%-13.21%-8.25%INDPIndaptus Therapeutics+2.44%-4.18%-35.38%-26.74%-76.88%LONAAthira Pharma+5.42%-16.18%-2.44%-12.88%+797,999,900.00%TKNOAlpha Teknova+0.75%-1.29%+1.91%+65.84%+29.93%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.57Moderate Buy$5.4094.24% UpsideINDPIndaptus Therapeutics 1.00SellN/AN/ALONAAthira Pharma 2.40Hold$15.0098.41% UpsideTKNOAlpha Teknova 1.50ReduceN/AN/ACurrent Analyst Ratings BreakdownLatest LONA, TKNO, EDIT, and INDP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026INDPIndaptus Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)7/17/2026TKNOAlpha Teknova Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/27/2026LONAAthira Pharma Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$20.005/11/2026LONAAthira Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.00(Data available from 7/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$40.52M6.72N/AN/A$0.28 per share9.93INDPIndaptus TherapeuticsN/AN/AN/AN/A$1.40 per shareN/ALONAAthira PharmaN/AN/AN/AN/A$2.98 per shareN/ATKNOAlpha Teknova$41.80M6.72N/AN/A$1.28 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)INDPIndaptus Therapeutics-$20.85M-$15.40N/AN/AN/AN/A-1,030.07%-299.69%8/17/2026 (Estimated)LONAAthira Pharma-$105.61M-$5.21N/AN/AN/AN/A-381.01%-225.74%N/ATKNOAlpha Teknova-$17.26M-$0.32N/AN/AN/A-41.07%-24.32%-16.34%8/5/2026 (Estimated)Latest LONA, TKNO, EDIT, and INDP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/17/2026Q2 2026INDPIndaptus Therapeutics-$1.57N/AN/AN/AN/AN/A8/11/2026Q2 2026EDITEditas Medicine-$0.30N/AN/AN/A$2.85 millionN/A8/5/2026Q2 2026TKNOAlpha Teknova-$0.0833N/AN/AN/A$10.96 millionN/A5/15/2026Q1 2026INDPIndaptus Therapeutics-$1.87-$0.23+$1.64-$0.23N/AN/A5/7/2026Q1 2026LONAAthira PharmaN/A-$1.73N/A-$1.73N/AN/A5/6/2026Q1 2026TKNOAlpha Teknova-$0.0926-$0.08+$0.0126-$0.08$10.23 million$11.08 million5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ALONAAthira PharmaN/AN/AN/AN/AN/ATKNOAlpha TeknovaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.223.22INDPIndaptus TherapeuticsN/A2.342.34LONAAthira PharmaN/A10.3810.38TKNOAlpha Teknova0.204.593.60Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%INDPIndaptus Therapeutics7.06%LONAAthira Pharma57.12%TKNOAlpha Teknova13.81%Insider OwnershipCompanyInsider OwnershipEDITEditas Medicine3.10%INDPIndaptus Therapeutics9.94%LONAAthira Pharma25.73%TKNOAlpha Teknova13.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableINDPIndaptus Therapeutics6113.24 million101.99 millionNot OptionableLONAAthira Pharma409.39 million6.98 millionNo DataTKNOAlpha Teknova24053.61 million46.54 millionNot OptionableLONA, TKNO, EDIT, and INDP HeadlinesRecent News About These CompaniesTeknova to Report Second Quarter 2026 Financial Results on August 5, 20262 hours ago | globenewswire.comAlpha Teknova, Inc. $TKNO Holdings Boosted by Roubaix Capital LLCJuly 19 at 5:51 AM | marketbeat.comAlpha Teknova (NASDAQ:TKNO) Shares Down 2.2% - Should You Sell?July 16, 2026 | americanbankingnews.comAlpha Teknova (NASDAQ:TKNO) Shares Down 2.2% - What's Next?July 16, 2026 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO), Arcus Biosciences (RCUS) and Tenaya Therapeutics (TNYA)June 4, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Alpha Teknova (TKNO) and REPRO-MED Systems (KRMD)May 9, 2026 | theglobeandmail.comAlpha Teknova, Inc. (NASDAQ:TKNO) Just Released Its First-Quarter Results And Analysts Are Updating Their EstimatesMay 9, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q1 2026 Earnings Call TranscriptMay 8, 2026 | seekingalpha.comAlpha Teknova Charts Cautious Path to 2027 GrowthMay 7, 2026 | tipranks.comAlpha Teknova (TKNO) Q1 2026 Earnings TranscriptMay 6, 2026 | finance.yahoo.comTeknova Reports First Quarter 2026 Financial ResultsMay 6, 2026 | globenewswire.comTeknova to Report First Quarter 2026 Financial Results on May 6, 2026April 22, 2026 | globenewswire.comFavourable Signals For Alpha Teknova: Numerous Insiders Acquired StockMarch 30, 2026 | finance.yahoo.comAlpha Teknova (NASDAQ:TKNO) CEO Acquires $55,900.00 in StockMarch 10, 2026 | insidertrades.comTeknova outlines 20%-25% long-term revenue growth target while investing $2M annually in commercial capabilitiesFebruary 27, 2026 | seekingalpha.comAlpha Teknova Inc (TKNO) Q4 2025 Earnings Call Highlights: Navigating Growth Amid ChallengesFebruary 27, 2026 | finance.yahoo.comAlpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call TranscriptFebruary 26, 2026 | seekingalpha.comTeknova Reports Fourth Quarter and Full Year 2025 Financial ResultsFebruary 26, 2026 | globenewswire.comEarnings To Watch: Alpha Teknova Inc (TKNO) Reports Q4 2025 ResultFebruary 25, 2026 | finance.yahoo.comAlpha Teknova (TKNO): Investors are Waiting for Leading Indicators to Drive SalesFebruary 20, 2026 | insidermonkey.comTeknova to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026February 5, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 2026Uncle Sam Plugs In: Nuclear Energy’s Cash Flow Moment Is Finally HereBy Jeffrey Neal Johnson | June 26, 2026Strategy’s Bitcoin Pivot Gives Investors a New Reason to Watch Preferred SharesBy Jeffrey Neal Johnson | July 5, 2026Oracle Is One Step From Junk—Can It Afford the AI Boom?By Sam Quirke | July 21, 2026Buy, Hold, or Wait: 3 Small-Cap Stocks Telling Different StoriesBy Chris Markoch | July 21, 2026LONA, TKNO, EDIT, and INDP Company DescriptionsEditas Medicine NASDAQ:EDIT$2.78 -0.11 (-3.81%) Closing price 04:00 PM EasternExtended Trading$2.81 +0.03 (+1.12%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Indaptus Therapeutics NASDAQ:INDP$2.64 +0.12 (+4.76%) Closing price 04:00 PM EasternExtended Trading$2.60 -0.04 (-1.52%) As of 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Athira Pharma NASDAQ:LONA$7.56 -0.42 (-5.26%) Closing price 04:00 PM EasternExtended Trading$7.48 -0.07 (-0.99%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies. The company's product pipeline includes ATH-1020, an orally available brain-penetrant small molecule designed to enhance the HGF/MET system that is in Phase 1 clinical trials to treat neuropathic pain and neurodegenerative diseases; and ATH-1105, an oral small molecule drug candidate, which is a preclinical model for the treatment of Amyotrophic Lateral Sclerosis. In addition, it has a license agreement with Washington State University to offer for sale products covered by certain licensed patents, including dihexa, the chemical compound into which fosgonimeton metabolizes following administration; and collaboration and grant agreement with National Institutes of Health Grant to support ACT-AD Phase 2 clinical trial for fosgonimeton. The company was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. Athira Pharma, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.Alpha Teknova NASDAQ:TKNO$5.24 -0.10 (-1.87%) Closing price 04:00 PM EasternExtended Trading$5.24 0.00 (-0.10%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Alpha Teknova, Inc. produces critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits. The company serves its products to life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, as well as academic and government research institutions. Alpha Teknova, Inc. was founded in 1996 and is headquartered in Hollister, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Robotaxi Mode Engaged: Tesla Starts Monetizing Its Florida Fleet Insider Moves Are Sending Mixed Signals Across the Tech Sector Boxabl Disrupts Housing With A Tiny Float IPO Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying Velo3D Forges a New Reality After Its Sharp Stock Sell-Off Why Apple Could Be the Last One Standing in the Tech Wreck Archer and Anduril Put ACHR Stock on a New Defense Flight Path 3M's Redemption Arc: Can Q2 Earnings Change the Narrative? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
